Primecap Management
ZNTL icon

Primecap Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Primecap Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.64M Hold
957,420
– – ﹤0.01% 287
2026
Q1 		$2.24M Hold
957,420
– – ﹤0.01% 299
2025
Q4 		$1.29M Sell
957,420
-5,200
-0.5% -$7.57K ﹤0.01% 309
2025
Q3 		$1.45M Sell
962,620
-65,000
-6% -$97.4K ﹤0.01% 310
2025
Q2 		$1.19M Sell
1,027,620
-237,000
-19% -$313K ﹤0.01% 315
2025
Q1 		$2.01M Sell
1,264,620
-256,010
-17% -$552K ﹤0.01% 303
2024
Q4 		$4.61M Buy
1,520,630
+22,600
+2% +$74.1K ﹤0.01% 278
2024
Q3 		$5.51M Buy
1,498,030
+265,690
+22% +$966K ﹤0.01% 282
2024
Q2 		$5.04M Buy
1,232,340
+67,730
+6% +$756K ﹤0.01% 279
2024
Q1 		$18.4M Buy
1,164,610
+141,260
+14% +$1.94M 0.01% 231
2023
Q4 		$15.5M Sell
1,023,350
-10,400
-1% -$152K 0.01% 241
2023
Q3 		$20.7M Sell
1,033,750
-77,400
-7% -$1.96M 0.02% 229
2023
Q2 		$31.3M Sell
1,111,150
-17,770
-2% -$426K 0.03% 207
2023
Q1 		$19.4M Sell
1,128,920
-1,250
-0.1% -$25.3K 0.02% 228
2022
Q4 		$22.8M Sell
1,130,170
-49,530
-4% -$1.07M 0.02% 212
2022
Q3 		$25.6M Sell
1,179,700
-12,300
-1% -$336K 0.02% 202
2022
Q2 		$33.5M Sell
1,192,000
-16,590
-1% -$439K 0.03% 192
2022
Q1 		$55.8M Sell
1,208,590
-45,050
-4% -$2.43M 0.04% 179
2021
Q4 		$105M Sell
1,253,640
-81,980
-6% -$6.34M 0.07% 157
2021
Q3 		$89M Sell
1,335,620
-12,990
-1% -$749K 0.06% 160
2021
Q2 		$71.7M Buy
1,348,610
+13,180
+1% +$706K 0.05% 176
2021
Q1 		$57.9M Sell
1,335,430
-36,260
-3% -$1.56M 0.04% 185
2020
Q4 		$71.2M Sell
1,371,690
-11,060
-0.8% -$499K 0.05% 169
2020
Q3 		$45.2M Buy
1,382,750
+722,800
+110% +$25.3M 0.04% 171
2020
Q2 		$31.7M Buy
+659,950
New +$25.3M 0.03% 184

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Primecap Management's ZNTL Position: Q2 2026 in Review

Primecap Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 957,420 shares worth $4.64M. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Primecap Management first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $105M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Primecap Management held 957,420 shares of Zentalis Pharmaceuticals worth $4.64M as of Q2 2026.
  • Primecap Management left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Primecap Management's portfolio in Q2 2026, its #287 holding.
  • Primecap Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Primecap Management's Zentalis Pharmaceuticals position peaked at $105M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.